

#	
41BBL	PO-018
5-FU	PO-047
6-MPA	PO-057
A	
Acinar cell plasticity	PO-075
Acinar-to-ductal metaplasia	PO-073, PO-117
Adaptive	PO-050
Adenosquamous carcinoma of the pancreas	PO-054
ADM	PO-075
Advanced glycation end products	PO-065
Angiogenesis	PR-014
Animal model	PO-066
Annamycin	PO-066
Anti-PD1	PO-020
Anti-tumor immunity	PO-019
Arsenic Trioxide	PO-058
Arginase 1	PO-116
Artificial Intelligence	PO-012
Ascorbate	PO-015
ATAC-seq	PO-067
AU-rich elements	PO-017
Autophagy	PO-031
B	
Bacteria	PO-033
BET inhibitor(s)	PO-045, PO-122
Biobank	PO-077
Biomarker	PO-006, PO-008, PO-009
C	
Cachexia	PO-023
Cancer associated fibroblasts (CAFs)	PO-080, PO-100, PO-107, PO-110, PO-114, PO-117, PO-121
Cancer associated fibroblast plasticity	PO-113
Cancer stem cells	PR-004

Cancer stem-like cells	PO-045
Cancer associated cachexia	PO-029
Cathepsin B	PO-110
CBD-II12	PO-020
CCR1	PO-129
CD40	IA-002
CD40L	PO-018
CD8 T cells	PO-116
CDK inhibitor	PO-122
CDK4/6	PO-031
CDKN2A	PO-122
Cell motility	PO-040
Cellular origin	PO-103
Cell senescence	PO-065
Cell surfaceome	PR-006
Chromatin-remodeling domain	PO-048
circRNA	PO-006, PO-026
c-Jun N-terminal protein kinases	PO-093
Clinical trial	PO-050, PO-055
Clostridium novyi-NT	PO-037
C-MET	PO-074
Co-culture	PO-080
Cold tumor	PO-020
Collagen	PO-020
Combination therapy	PO-051
CPI-613	PO-024
CPSF3	PO-034
CRISPR	PO-037
Crosstalk	PO-130
CSF-1	PO-106
CXCL1	PO-125
Cytidine deaminase	PO-043
CyTOF	PO-098
D	
Deconvolution	PO-004
Debate	IA-007
Deep Learning	PO-014

Dendritic cells	IA-002
Dependency Map	PR-006
Desmoplasia	PO-017, PO-100
DFMO	PO-119
Diagnostics	PO-008
Directed evolution	PO-016
Dissemination	PO-082
DNA methylation	PO-090
DNR	PO-003
Drug repurposing	PO-040
Drug testing	PO-077

E

Early detection	PO-007, PO-010
EGFR	PO-086
EMT	PR-010
Epidemiology	IA-004
Epigenetics	PR-008
Epigenomics	PR-005
Epithelial-mesenchymal transition (EMT)	PO-059, PO-090
ErbB2	PO-057
EZH2	PO-124

F

Fibroblast(s)	PO-102, PO-123, PR-013, PR-016
focal adhesion kinase	PR-004
FOLFIRINOX	PO-076
Fra-1	PR-005
Fuel burning	PO-029

G

G protein-coupled receptor	PO-091
Gα13	PO-094
Gemcitabine	PO-108
Gene regulation	PO-095
Genetic education	PO-013
Genetic testing	PO-013
Genetically engineered mouse models	PO-084

Germline variants	PO-011
Glutamine	IA-005
Glycocalyx	PO-044
Glycolysis	PO-021, PO-026

H

HBP1	PO-082
Health disparities	IA-004
Hedgehog signaling	PR-014
Hereditary pancreatic cancer	PO-011
Heterogeneity	PO-061, PO-107
Hispanic	PO-062
Histamine	PO-091
Histones	PO-034
HNF1A	PO-045
Human epidermal growth factor receptor 3 (HER3)	PO-131
Humanized mouse model	PO-065
Human tumor models	IA-008
HuR	PO-017
Hypoxia	PO-025, PO-027, PO-126
Hypoxia adaptations and autophagic flux	PO-002

I

IL33	PO-102
IL-4/13	PO-092
Immune cell spatial profiling	PO-118
Immune checkpoint genes	PO-101
Immune evasion	PO-063
Immune microenvironment	PO-103, PO-114
Immune profiling	PO-046
Immune suppression	PO-104, PO-129
Immune therapy	PR-002
Immune-regulation	PO-059
Immunoediting	PR-003
Immunology	PR-001
Immunostaining	PO-014
Immunotherapy	PO-004, PO-018, PO-049, PO-063, PO-072, PO-105, PO-112

Immunotherapy resistance	PR=004
Insulin receptor signaling	PO-056
Integrated Stress Response	PO-088
Interleukin-13-receptor alpha 1	PO-092
Interleukin-8	PO-098
Intraductal papillary mucinous neoplasm	PO-067
Invasion	PO-121, PO-126
IPMN	PO-103
J	
JNK1/2	PO-093
K	
Kdm6b	PR-008
Keratin 17	PO-048
KPC/KPC model/KPC mice	IA-007, IA-008, PO-076
KRAS	PO-102, PR-010, PR-016
KRAS oncogene	PO-089
Kras ^{G12D}	PR-011
L	
Laminin γ 2 (LAMC2)	PO-038
Lineage reversion	PR-005
Lipid	PR-009
Lipid homeostasis	PO-025, PO-027
Liver endothelium	PO-131
Locally-advanced pancreatic cancer	PO-097
Long-term pancreatic cancer survivors	PR-003
Long-term survival	PO-118
Losartan and neoadjuvant chemotherapy	PO-097
LP-184	PO-036
M	
Machine Learning	PO-012
Macrophage(s)	PO-114, PO-116, PO-120, PR-016
Macropinocytosis	PO-130
Mast cells	PO-091
Master Regulators	PO-001

Mechanobiology	PO-044
Mesothelin	PO-115
Meta-analysis	PO-008
Metabolic reprogramming	PO-048
Metabolism	IA-005, PO-023, PR-015
Metastases	PO-074
Metastasis	PO-038, PO-057, PO-059, PO-061, PO-106, PO-123, PR-010
Metastatic	PR-002
Metastatic PDAC	PO-050
MFU	PO-047
Microenvironment	PO-095, PR-015
Micro-RNA	PO-052
Minnelide	PO-054
MNK kinases	PO-049
Molecular subtypes	IA-001, PR-006
Mouse models	PO-060, PO-094
MPC1	PO-021
mRNA translation	PO-088
mTOR	PO-094
Mucins	PO-044
Multimomics	PO-007
Multiple primary tumors	PO-011
MYC	PO-061, PO-081
Myc inhibitor	PO-054
N	
Neoadjuvant	PO-055
Neoadjuvant therapy	PO-046
Neoantigen quality	PR-003
Netrin G1 ligand	PO-096
Neutrophil extracellular traps	PO-125
Nischarin	PO-040
NK cells	PO-124
Notch4	PO-073
Novel drug	PO-039
Nuclear Pores	PO-081
Nutritional stress	PO-025

O

ONC212	PO-064
Oncolytic bacteria	PO-037
Oncolytic virus	PO-016, PO-017
Organoids	PO-062, PO-077
Organotropism	PR-007
Origin	PR-013
Ornithine aminotransferase	PO-028

P

Prrx1	PO-075
p53	PO-084
Palbociclib	PO-031
Pancreas cancer	PO-010, PO-012, PO-057
Pancreatic	PO-015
Pancreatic adenocarcinoma	PO-024 IA-001, IA-005, IA-008, PO-003, PO-006, PO-007, PO-013, PO-023, PO-028, PO-036, PO-043, PO-052, PO-056, PO-058, PO-060, PO-092, PO-093, PO-096, PO-104, PO-108, PO-110, PO-115, PO-123, PO-131, PR-001
Pancreatic cancer-associated fibroblasts	PO-130
Pancreatic cancer therapy	IA-007
Pancreatic cyst fluid	PO-009
Pancreatic ductal adenocarcinoma	PO-001, PO-005, PO-026, PO-038, PO-072, PO-111
Pancreatic intraepithelial neoplasia (PanIN)	PO-056, PO-103
Pancreatic stellate cells	PO-113
Patient-derived organoids	PO-067, PO-070
PDAC	PO-020, PO-041, PO-064, PO-068, PO-082, PO-086, PO-103, PO-127, PR-011, PR-015
PDAC Atlas	PO-111
PDAC organoids	PO-021, PO-121
PDX	PO-079
Percent conversion	PO-047
Phase 2	PR-002

Phase 3 trial in progress	PO-051
PIN1 prolyl isomerase	PO-113
Plasma cells	PO-019
Plasminogen	PO-127
Polyamine(s)	PO-028, PO-120
Precision oncology	PO-070
Predictive factors	PO-052
Programmed cell death ligand-1	PO-058
Proteome profiling	PO-005
Proteomics	IA-003, PO-079
PTGR1	PO-036

Q

There were no keywords in this range.

R

Racial disparity	PO-005
RAD51 inhibitor	PO-039
Radiation	PO-126
Radiation sensitization	PO-024
Radiofrequency ablation	PO-101
Radiomics	IA-004
Radiotherapy	PO-112
Raf1	PO-086
Readmission	PO-003
Regulatory B cells	PO-019
Regulatory Network	PO-001
Replication stress	PO-081
Replicative stress	PO-043
RHAMM	PO-060
Risk stratification	PO-009
RNA sequencing	PO-002

S

Sarcomatoid carcinoma	PR-008
SCAP	PR-009
scRNA-seq	PO-068, PO-111
Segmentation	PO-014

Sendai virus	PO-041
Senescence	PO-124
Serine metabolism	PO-088
Single cell transcriptomics	PO-084
Single-cell RNA sequencing	PO-098
Solid lipid nanoparticle	PO-108
Spheroids	PO-074
Splanchnic	PR-013
SREBP	PR-009
SRSF1	PR-011
Stromal barriers	PO-105
Stromal reprogramming	PO-112
Stromal-epithelial crosstalk	PO-117
Subtype(s)	PO-004, PO-055, PR-007
Survival	PO-120
Synergy	PO-039
Synthetic biology	PO-033
Systemic metabolism	PO-029

T

Treatment-naïve	PO-046
T cell infiltration	PO-072
T cell receptor diversity	PR-007
T-cell(s)	IA-002, PO-064, PO-119
Targeted therapies	PO-089
TGF- β	PO-090
Therapeutic target(s)	IA-001, PO-073
TIGIT	PO-063
Tissue engineering	PO-069
Toll-like receptor	PO-105
Toxin	PO-033
Transcriptome analysis	PO-097
Transduction	PO-041
Treatment-induced vulnerabilities	PO-070
Trial	PO-015
Tumor associated macrophage(s)	PO-049, PO-129
Tumor associated neutrophil	PO-125
Tumor explants	PR-014

Tumor immune microenvironment	PO-118
Tumor immunology	PO-095
Tumor intrinsic genes	PO-002
Tumor microenvironment	PO-012, PO-080, PO-096, PO-100, PO-101, PO-106, PO-107, PO-115, PO-119, PR-001
Tumor model	PO-062
Tumor organoids	PO-089
Tumor resistance	PO-016
Tumor Treating Fields (TTFields)	PO-051

U

Ubiquitin	PO-057
Unfolded protein responses	PO-027
Uptake	PO-066
Urokinase	PO-127

V

YSM	PO-058
-----	--------

W

WNT signaling	PO-104
---------------	--------

X

There were no keywords in this range.

Y

There were no keywords in this range.

Z

There were no keywords in this range.